Copyright
©The Author(s) 2019.
World J Psychiatr. Jan 4, 2019; 9(1): 7-29
Published online Jan 4, 2019. doi: 10.5498/wjp.v9.i1.7
Published online Jan 4, 2019. doi: 10.5498/wjp.v9.i1.7
Details | Any anxiety disorder | Individual anxiety disorders |
Meta-analytic reviews | ||
Kowatch et al[29], 2005. 7 studies of child and adolescent BD (n = 362) | Mean prevalence of any anxiety disorder in BD 27% (range 14%-43%) | |
Vázquez et al[18], 2014. 46 studies of anxiety comorbidity in BD | Lifetime prevalence in epidemiological and clinical studies - mean 47% (range 24%-88%) | Mean prevalence: PD 22% (1%-40%), PHOBIAS 22% (2%-59%), GAD 20% (7%-42%), PTSD 16% (3%-39%), OCD 13% (5%-48%) |
Amerio et al[30], 2015. 46 studies of comorbid BD and OCD | Pooled prevalence of OCD in BD 17.0%; pooled prevalence of BD in OCD 18.0% | |
Nabavi et al[11], 2015. 52 interview-based studies of outpatients and inpatients | Lifetime prevalence of any anxiety disorder in BD 43% | Lifetime prevalence of: PD 17%, GAD 14%, SAD 13%, PTSD 11%, SP PHOBIA 11%, OCD 11%, AGORA 8% |
Pavlova et al[19], 2015. 40 studies (n = 14914) of community and clinical population | Lifetime prevalence of anxiety disorder in BD 45% | Lifetime prevalence of: GAD 20%, SOC PHOBIA 20%, PD 19%, PTSD 17%; no differences between BP I and BP II |
Tonna et al[31], 2015. 4 studies of adolescent BD- OCD (n = 345) | Pooled prevalence of comorbid OCD in BD among adolescents 23%; greater than adults (14%) | |
Amerio et al[32], 2016. 14 studies of comorbid BD and OCD in BP I and BP II | Pooled prevalence of OCD in BP I 22%; pooled prevalence of BP I in OCD 4% and of BP II in OCD 13.5% | |
Preti et al[33], 2016. 28 studies of comorbid BD and GAD (n = 7894) | Current prevalence 12% and lifetime prevalence 15% of GAD in BD | |
Taskiran et al[34], 2016. 33 studies of child and adolescent BD | Prevalence of any anxiety disorder in BD 44% | Prevalence of: GAD 25%, SEP ANX 22%, OCD 17%, SOC PHOBIA 15%, PD 10% |
Pavlova et al[35], 2017. 10 studies of euthymic BD (n = 2120) | Current prevalence of any anxiety disorder in BD 35% | Current prevalence of: GAD 12%, SAD 10%, SP PHOBIA 10%, OCD 7% |
Yapici Eser et al[20], 2018. 135 studies of comorbid BD and anxiety disorders | Lifetime prevalence 41% and current prevalence 38% of anxiety disorder in BD; lifetime prevalence 38% in BD I and 34% in BD II; current prevalence 31% in BD I and 37% in BD II | Lifetime prevalence: PD 18%, GAD 13%, SAD 13%, OCD 10%; current prevalence: GAD 15%, PD 13%, SAD 12%, OCD 10%; prevalence PD and SAD significantly affected by proportion of BD I patients |
Preti et al[36], 2018. 15 studies of comorbid BD and PD (n = 3391) | Lifetime prevalence: PD 16%; current prevalence: PD 13%; no difference between BP I and BP II | |
Systematic reviews | ||
Strakowski et al[37], 1994. 4 studies of anxiety comorbidity in BD | Mean prevalence: PD 7%-16%, OCD 8%-13% | |
Krishnan[38], 2005. 10 studies of anxiety comorbidity in BD | Mean rate 71% (range 49%-92%) | Mean rates: SOC PHOBIA 47%, PTSD 39%, PD 11%, OCD 10% |
McIntyre et al[8], 2006. 17 studies of anxiety comorbidity in BD | Lifetime rates 16%-79% in 11 studies; usually 30%50%; current prevalence 15%-56% in 8 studies | AGORA lifetime 22%-62%; current 6%-7%; SP PHOBIA lifetime 2%-67%; current 8% SOC PHOBIA lifetime 4%-47%; current 13%-19% GAD lifetime 3%-43%; current 2%-25% PTSD lifetime 7%-37%; current 4%-40% PD lifetime 2%-38%; current 8%-26% OCD lifetime 2%-31%; current 6%-8% |
Tamam[9], 2007. 15 studies of anxiety comorbidity in BD | Lifetime prevalence in epidemiological and clinical studies 24%-93% | Lifetime prevalence of: SOC PHOBIA 5%-47%, PD 6%-43%, OCD 7%-39%, GAD 3%-43%, PTSD 7%-21% |
Kauer-Sant'Anna et al[15], 2009. 9 studies of anxiety comorbidity in BD | Lifetime prevalence in epidemiological studies 48%-93% | SP PHOBIA 10%-67%, SOC PHOBIA 8%-47%, PTSD 7%-39%, GAD 3%-42%, PD 5%-33% |
Quarantini et al[39], 2009. PTSD prevalence in BD | Lifetime rates of PTSD in BD 16%-39% | |
Maina et al[16], 2011. 11 studies of anxiety comorbidity in BD | Lifetime prevalence in epidemiological studies 63%-89%; in clinical samples 11%-79% | PD 4%-39%, OCD 3%-35%, GAD 3%-32%, SOC PHOBIA 2%-31%, PTSD 5%-29% |
Pallanti et al[40], 2011. 10 studies of comorbid BD and OCD | Lifetime prevalence in epidemiological and clinical studies 15%-35% | |
Lala et al[41], 2012. 7 studies of elderly patients | PTSD 5%-11%, PD -current 22%, GAD-current 16%, OTHERS 10%-11% | |
Schaffer et al[10], 2012. 9 studies of anxiety comorbidity in BD | Lifetime prevalence in epidemiological studies 52%-75% | Lifetime prevalence: OCD 10%-25%, PD 14%-27%, PTSD 16%-39% |
Latalova et al[22], 2013. 12 studies of anxiety comorbidity in BD | Lifetime prevalence in epidemiological studies 75%; in clinical samples 27%-56% | Lifetime prevalence: SOC PHOBIA 47%-52%, SAD 38%, SP PHOBIA 35%, GAD 30%, PTSD 24% (16%-39%), PD 20%, OCD 14% (3%-35%) |
Amerio et al[42], 2014. 64 articles of comorbid BD and OCD | Lifetime prevalence of OCD in BD 11%-21% (mean BP I 15%, BP II 13%); lifetime prevalence of BD in OCD 6%-10% (mean BP I 4%, BP II 9%) | |
Frías et al[43], 2015. 167 studies of child and adolescent BD | Mean prevalence of any anxiety disorder in BD 54% (range 41%-80%) | GAD and SEP ANX rates higher than other disorders; OCD 36%-39%, PD 18%-23%, PTSD 8% |
Sharma[44], 2017. 8 studies of post-partum BD comorbidity | Anecdotal reports of simultaneous onset of comorbid BD-OCD in the postpartum period |
Ref. | Any anxiety disorder | Individual anxiety disorders |
Himmelhoch[45], 1998 | Lifetime prevalence of PD in BD 21%; prevalence of BD in PD 14%-34% | |
Hantouche et al[46], 2002 | Prevalence of BD in OCD 11%-16%, cyclothymia 50%-56% | |
Freeman et al[6], 2002 | Lifetime and current rates 32%-79% | SOC PHOBIA lifetime 8%-47%; PTSD lifetime 39%; current 40%-43%; PD lifetime 11%-21%; current 2%-9%; OCD lifetime 9%-21%; current 35% |
McIntyre et al[47], 2003 | Lifetime rate 92% | Lifetime rates SP PHOBIA 67%, SOC PHOBIA 47%, GAD 42%, PTSD 39%, PD 33% |
Sasson et al[12], 2003 | Lifetime rate 60%-65% | SOC PHOBIA 10%-40%, OCD 7%-35%, SP PHOBIA 10%, PTSD 7%, GAD 3% |
Ghaemi[48], 2004 | Lifetime rate > 90% | GAD 50%, PD 20%, OCD 20% |
Goldberg et al[2], 2004 | Epidemiological studies > 90%; clinical 4%-50% | |
Issler et al[13], 2004 | Lifetime rate 24% to 79% | |
McIntyre et al[49], 2004 | Lifetime rate 42%-90%; current rate 30% | PD 9%-20%, SOC PHOBIA 13%-16%, SP PHOBIA 8%-10%, GAD 3%, OCD 8%-9%, PTSD 4%-7% |
Otto et al[50], 2004 | Mean prevalence of PTSD in BD 16% | |
Bauer et al[14], 2005 | Lifetime rate 16%-42% and current rate 30%-31% in clinical studies | PTSD lifetime 7%-50%; current 4%-40% PD lifetime 4%-38%; current 8% OCD lifetime 3%-35%; current 6%-8% GAD lifetime 3%-32%; current 2%-3%; SOC PHOBIA lifetime 0%-31%; current 13% SP PHOBIA lifetime 10%-20%; current 8% |
Hirschfeld et al[24], 2005 | Lifetime rate 42%-92% | PD 21% OCD 21% |
Simon et al[51], 2005 | Lifetime rate 50%; current rate 30% | PD lifetime rates 14%-38%; PD current rates 4%-9% |
Baldassano[52], 2006 | Lifetime rate 51%-65%; current rate 7% | |
Keller[27], 2006 | Lifetime rates 51%-65% | |
MacKinnon et al[53], 2006 | Prevalence PD - community studies 12%-35%; clinical studies 5%-63%; family studies 11%-21% | |
Sajatovic et al[54], 2006 | Prevalence 23% among elderly patients | Prevalence PTSD 44%, others 43%, GAD 23%, PD 6%, OCD 5%, AGORA 3%, SOC PHOBIA 0.5%, SP PHOBIA 0.2% |
Singh et al[55], 2006 | Mean prevalence 55% | Mean prevalence SOC PHOBIA 47%, PTSD 16%, PD 11%, OCD 10% |
Dineen Wagner[56], 2006 | Prevalence in community studies 29%-50% and clinical samples 14%-76% of anxiety comorbidity in child and adolescent BD | Prevalence: OCD 9%-49%, SOC PHOBIA 3%-33%, GAD 19%-20%, SEP ANX 13%-57%, AGORA 15%-27%, PD 6%-11%, PTSD 18% |
Bhagwagar[21], 2007 | Lifetime rate > 50% | |
MacKinnon[57], 2007 | Prevalence PD 15%-20% | |
Mantere[28], 2007 | Lifetime rate 42%-56%; current rate 30% | |
El-Mallakh et al[17], 2008 | Lifetime rate 87%-92% in epidemiological studies | Lifetime rates: SAD 5%-52%, GAD 30%-42%, PTSD 16% -39%, OCD 17%-21,% PD 21% |
Jolin et al[58], 2008 | Mean prevalence 14%-77%% in childhood and adolescent BD | Mean prevalence: SEP ANX 18%-22%, PHOBIA 4%-11%, PD 3%-11%, OCD 3% |
Joshi et al[59], 2009 | Prevalence in adults and children 12%-76% | Prevalence OCD 15-35% |
Sagman et al[60], 2009 | Lifetime rate 50%-65%; current rate 30% | |
Simon[61], 2009 | Lifetime rate 51% | Lifetime rate GAD 18% |
Bowden[62], 2010 | Lifetime rate 92% | |
Saunders et al[4], 2010 | Lifetime rate 65% | Lifetime rate OCD 21% |
Andrade-Nascimento et al[63], 2012 | Current 15% and lifetime prevalence 16% of GAD in euthymic patients | |
Jana et al[64], 2012 | Mean prevalence of OCD 0%-54% in childhood and adolescent BD | |
McIntyre et al[65], 2012 | Lifetime rate 63%-87% | |
Perugi et al[66], 2012 | Lifetime rate 30%-93%; current rate 30% | Lifetime rate SP PHOBIA 67%, PD 33% |
Cazard et al[67], 2013 | Mean prevalence 5%-33% | Mean prevalence: SOC PHOBIA 0.5%-47%, PTSD 2%-44%, GAD 3%-42%, OCD 1%-14% |
Amerio et al[68], 2015 | Mean prevalence 50% | OCD 17%-18% |
Chang et al[69], 2016 | Lifetime rate 51%-90%; current rate 31% | |
Ketter[23], 2015 | Lifetime prevalence mean 48% (range 17%-79%) | |
Shi[70], 2015 | Prevalence rate of OCD in BD 11%-21% | |
Tonna et al[71], 2015 | Prevalence rate of OCD in BD 21% |
Any anxiety disorder | Individual anxiety disorders | |
Lifetime prevalence rates | ||
ECA[72-74] | OCD 21%, PD 21% | |
NCS[75-77] | BD 93% | SP PHOBIA 67%, AGORA 62%, SOC PHOBIA 47%, GAD 43%, PTSD 39%, PD 33%, OCD 21% |
NCS-R[78-80] | ANY BD 75%, BP I 87%, BP II 83%-89%, ST-BD 63%-72% | SOC PHOBIA 38%, SP PHOBIA 35%, SAD 35%, GAD 30%, PTSD 24%, PD 20%, OCD 14%-23%, AGORA 6% |
WMH[81] | Bipolar spectrum 63%, BP I 77%, BP II 75%, ST-BD 53% | 1SP PHOBIA 30%, 1SAD 29%, SOC PHOBIA 26%, GAD 20%, PTSD 19%, OCD 12%, PD 11%, AGORA 6% |
NESARC[82-84]2 | BD 60%, BP I 65%, BP II 45% | PD 53%, GAD 51%, SAD 48%, SP PHOBIA 21%-34%, PD 19%-33%, GAD 18%-32%, SOC PHOBIA 18%-26%, AGORA 0.2%-1% |
Edmonton, Alberta, Canada[87] | PHOBIA 54%, PD 18%, OCD 15% | |
OADP study[88] | 33% among adolescents with BD | SEP ANX 18%-22%, PHOBIA 4%-11%, PD 3%-11%, OCD 3% |
Zurich Cohort Study[89] | Hypomania - any anxiety disorders 46%- 78% | SOC PHOBIA 10%-36%, AGORA 7%-29%, SP PHOBIA 10%-23%, PD 12%-22%, OCD 5%-6% |
National Epidemiologic Survey, Hungary[90] | BD 39% | GAD 14%, SP PHOBIA 13%, PD 11%, AGORA 9%, SOC PHOBIA 8%, OCD 3% |
Population-based study from Hungary[91] | BP I 54%, BP II 100% | AGORA 22%-37%, GAD 10%-21%, SP PHOBIA 9%-17%, PD 7%-12%, SOC PHOBIA 4%-12% |
Sesto Fiorentino Study, Italy[92] | In BD and ST-BD: GAD 28%-39%, SOC PHOBIA 13%-20%, OCD 16%-17%; PD 6%-16%, SP PHOBIA 4% | |
EDSP study[93] | BP I 55%, BP II 59%, ST-BD 53% (in 14-24-year-olds with BD) | SP PHOBIA 19%-38%, GAD 10%-18%, SOC PHOBIA 14%-16%, AGORA 5%-16%, OCD 3%-16%, PD 3%-12%, PTSD 9%-11% |
Canadian Community Health Survey[94,95] | BD 52%-61% | |
Singapore Mental Health Study[96] | In BD: OCD 26%, GAD 18% | |
Current prevalence rates | ||
Australian National Survey[97] | BD 52% | PD 26%, GAD 25%, SOC PHOBIA 19%, PTSD 11%, OCD 9%, AGORA 6% |
Australian National Survey[98] | BD 7%-9% | SOC PHOBIA 5%-7%, PTSD 4%-7%, GAD 4%-6%, PD 4%-5%, OCD 4%-5%, AGORA 2%-3% |
Canadian Community Health Survey[99] | BD 29% | SOC PHOBIA 17%, PD 13%, AGORA 3% |
Any anxiety disorder | Individual anxiety disorders | |
Stanley foundation studies | ||
McElroy et al[100], 2001 (n = 288) | Lifetime rate 42%; Current rate 30% | PD lifetime 20%, current 9%; SOC PHOBIA lifetime 16%, current 13%; SP PHOBIA lifetime 10%, current 8%; OCD lifetime 9%, current 8%; PTSD lifetime 7%, current 4%; GAD lifetime 3%, current 3% |
Suppes et al[101], 2001 (n = 261) | Lifetime rate 44% | |
Dittmann et al[102], 2002 (n = 152) | Lifetime rate 12% | |
Levander et al[103], 2007 (n = 350) | Lifetime rate BD 46%; BP I 45%-48%; BP II 38%-58% | |
Altshuler et al[104], 2010 (n = 711) | Lifetime rate: women 46%, men 29% | Lifetime rates: PD women 21%, men 14%; SOC PHOBIA women 12%, men 10%; SP PHOBIA women 12%, men 4%; OCD women 12%, men 7%; PTSD women 11%, men 3%; AGORA women 3%, men 2% |
STEP-BD | ||
Kogan et al[105], 2004 (n = 1000) | Lifetime rate 47% | |
Perlis et al[106], 2004 (n = 983) | Prevalence rate 38%-69% | SOC PHOBIA 13%-31%, GAD 13%-29%, PD 14%-27%, PTSD 11%-27%, OCD 8%-13%, AGORA 5%-11% |
Simon et al[107], 2004 (n = 475) | Lifetime rate BD 51%; BP I/BP II 53%/46%; Current BD 30%; BP I/BP II 34%/19%; | Lifetime BD: SAD 22%, GAD 18%, PD 17%, PTSD 17%, OCD 10%, AGORA 8%; current BD: SAD 13%, PD 8%, OCD 6%, PTSD 5%, AGORA 4%, GAD 2% |
Simon et al[108], 2004 (n = 919) | Current rate 32% | GAD 13%, SAD 13%, PD 8%, OCD 7%, PTSD 5%, AGORA 4% |
Otto et al[109], 2006 (n = 1000) | Current rate 32% | Current rates: SAD 13%, GAD13%, PD 8%, OCD 7%, PTSD 5%, AGORA 4% |
Simon et al[110], 2007 (n = 120) | Lifetime rate 62%; current rate 29% | GAD lifetime 31%, current 13%; SAD lifetime 27%, current 14%; PD lifetime 22%, current 5%; PTSD lifetime 27%, current 11%; OCD lifetime 11%, current 6%; AGORA lifetime 9%, current 2% |
Other studies | ||
Vieta et al[111], 2001 (n =129) | PD 2%, SOC PHOBIA 2%, SP PHOBIA 2%, OCD 2% | |
MacKinnon et al[112], 2002 (n = 192) | Prevalence PD 14% | |
Henry et al[113], 2003 (n = 318) | Lifetime rates 24% | Lifetime rates: PD 16%, PHOBIAS 11%, OCD 3% |
Boylan et al[114], 2004 (n = 138) | Prevalence 56% | |
Bauer et al[14], 2005 (n = 328) | Lifetime rate 43%; current rate 38% | PTSD lifetime 28%, current 25%; PD lifetime 20%, current 17%; OCD lifetime 11%, current 8% |
Mantere[28], 2007 (n = 191) | Lifetime rate: BD 53%, BP I 46%, BP II 60%; current rate: BD 45%, BP I 36%, BP II 52% | PD lifetime 32%, current 24%; SOC PHOBIA lifetime 26%, current 18%; PTSD lifetime 16%, current 10%; GAD lifetime 15%; SP PHOBIA lifetime 8%, current 8%; OCD lifetime 5%, current 2%; AGORA lifetime 3%, current 2% |
Azorin et al[115], 2009 (n = 1090) | Lifetime rate 27% | Lifetime rates: GAD 20%, PD 5%, AGORA 4%, SOC PHOBIA 2%, PTSD 2%, OCD 1.5% |
Coryell et al[116], 2009 (n = 259) | Lifetime rates: PHOBIA 3%-6%, GAD 1%-5%, PD 1%-4%, OCD 2% | |
Gao et al[117], 2010 (n = 564) | Prevalence in RCBD 46% | |
Guo et al[118], 2010 (n = 136763) | Prevalence 36%-37% | |
Mantere et al[119], 2010 (n =191) | Current rate 31%-44% | |
Fracalanza et al[120], 2011 (n = 186) | Current rate 33% | Current rates: SAD 39%, PD 31%, OCD 16%, GAD 10%, PTSD 3% |
Goes et al[121], 2012 (n = 1416) | Prevalence: PD 23%, SP PHOBIA 10%, SOC PHOBIA 8%, OCD 6% | |
Chang et al[122], 2012 (n = 325) | Lifetime rates: BP I 27%, BP II 39% | Lifetime rates (BPI/BP II): GAD 10%/29%, PD 5%/9%, SOC PHOBIA 4%/5%, PTSD 3%/2%, OCD 2%/4%, SP PHOBIA 1%/4% |
Angst et al[123], 2013 (n = 903) | Mean prevalence: BP I 17%; BP II 27% | Mean prevalence (BP I/BP II): GAD 6%/12%, PD 12%/18%, SOC PHOBIA 5%/8%, OCD 6%/11% |
Castilla-Puentes et al[124], 2013 (n = 8129 youth) | Prevalence: Non RCBD 51%; RCBD 65%; BP I 41%-65%; BP II 69%-75%; | Prevalence (RCBD): GAD 55%, SAD 44%, OCD 11%, PTSD 9%, PD 9%, SP PHOBIA 8% |
Young et al[125], 2013 (n = 304) | Lifetime rate 22% | PD 40%, SP PHOBIA 24%, OCD 15%, GAD 13%, SAD 10%, AGORA 8% |
Asaad et al[126], 2014 (n = 350) | Prevalence 2.3% | |
Baek et al[127], 2014 (n = 417) | Lifetime rate 30% | Lifetime rates: PD 13%, SP PHOBIA 13%, OCD 13%, SOC PHOBIA 9% |
Principal findings | Ref. | |
Demographic correlates | ||
Age | Higher prevalence in younger patients with BD | [8,20,30,32,40,42] |
No differences in rates according to age | [9,33,36,70] | |
Gender | Higher prevalence among women | [8-10,14,16-18,24, 40] |
No gender differences | [30,32,33,36,42,52,69,70] | |
Marital status | No differences according to marital status | [20,70] |
Education | Higher levels more comorbidity | [20] |
Lower levels greater comorbidity | [8,9,14,66] | |
No effect of education | [33,36,70] | |
Socioeconomic status | Greater comorbidity among those with lower socioeconomic status | [8,9,14,74] |
No effect of socioeconomic status | [33,36] | |
Ethnic and cross-national differences | Differences in comorbidity across nations and ethnicities | [11,16,19,30,69,74,135] |
Clinical correlates | ||
Age of onset | Lower age of onset is associated with higher levels of comorbidity | [8-10,14,16-18,20,21-24,27,30,31,33,36,40,42,49,52,56,57,60,66,70,136-142] |
BP I vs BP II | Greater comorbidity in BP I | [15,17,30,33,49,60,84] |
Greater comorbidity in BP II | [4,9,20,128] | |
No clear differences in comorbidity between BP I and BP II | [7,8,10,16,18,19,28,32,36,42,50,52,66,69,78-81,93,137] | |
Depression | Anxiety comorbidity is associated with more frequent and severe depressive episodes | [8,10,14-17,26,36,42,49,52,57,66,69,137-139,143] |
No clear evidence of predominance of depressive pathology | [19,28,70] | |
Mania | Anxiety comorbidity is associated with more frequent and severe manic episodes | [8,16,19] |
No clear evidence of association with mania | [14,18,28,36,40,49,70] | |
Euthymia | Anxiety comorbidity is associated with shorter durations of euthymia | [8,9,14,16,17,21,22,50,52,66,67,69] |
Rapid cycling and mixed features | Anxiety comorbidity is associated with rapid cycling and mixed states | [8-10,13,15-18,40,49,52,67,69,141,142] |
No association with rapid cycling and mixed features | [19,28,66,70,144] | |
Psychotic symptoms | Anxiety comorbidity is associated with psychotic symptoms | [5,8,16,20,22,25,40] |
No association with psychotic symptoms | [70] | |
Insight | Anxiety comorbidity is associated with greater insight | [9] |
Cognitive impairment | Anxiety comorbidity is associated with greater cognitive impairment | [15, 66] |
Bipolar spectrum | Anxiety comorbidity is associated with bipolar spectrum disorders | [7,8,40,42,45,46,66,128] |
Subsyndromal symptoms | Anxiety comorbidity is associated with subsyndromal symptoms | [14,66,69,139] |
Substance-use disorders | Anxiety comorbidity is associated with greater prevalence of substance use and substance use disorders | [5,8-10,12-14,16-18,20,22-25,27,40,42,50,57,60,66,67,69,70,139,141-143] |
Other comorbidity | Anxiety comorbidity is associated with greater prevalence of ADHD, eating disorders, personality disorders. | [9,12,14,20,22,42,139,145] |
Impact | ||
Course of illness | Anxiety comorbidity is associated with poorer course and outcome in BD in terms of greater illness severity, frequent episodes, and greater risk of hospitalization | [5,8-10,13-18,20,22,23,26,27,33,36,40,42,49,52,56,57,60,70,128,137-139,141-143,146] |
Treatment response | Anxiety comorbidity is associated with poorer treatment response in BD | [4-6,8-10,12-14,16-18,22-27,40,49,57,60,66,67,69,137-139,141,142,146,147] |
Suicide | Anxiety comorbidity is associated with increased risk of suicidality in BD | [4,5,8-10,13,14-18,21-27,33,36,40,42,49,50,52,57,60,66,67,69,128, 136-139,141,142,148,149] |
Functioning | Anxiety comorbidity is associated with impaired functioning in BD | [8-10,14-18,21,22,25,27,33,36,40,42,49,50,66,67,69,128,139] |
Quality of life | Anxiety comorbidity is associated with impaired quality of life in BD | [8-10,14-17,21,22,25,27,36,39,42,50,66,67,138,139] |
Outcome of BD | Anxiety comorbidity is associated with incomplete remission and recovery in BD | [5,8,10,14,16,17,21,22,26,36,50,66,69,128,138] |
Adherence | Anxiety comorbidity is associated with irregular treatment-adherence in BD | [10,16] |
Delayed diagnosis-costs-service utilization | Anxiety comorbidity is associated with delayed diagnosis increased health-care utilization and costs in BD | [24,27,41,49 69,137] |
Findings | Ref. | |
Pharmacotherapy | ||
Evidence base | Few RCTs of treatment of comorbid anxiety disorders in BD | [7-10,15,22,26,49,55,60,141,142,157-162] |
RCTs of treatment of BD reporting change in anxiety symptoms as secondary outcomes | [6,10,26,15,16,25,33,49,162] | |
Principles of treatment | Mood stabilization is the first priority | [3,6,7,9,10,12,15,48,49,55,128,157-159,162] |
Add-on treatments | SGAs e.g., quetiapine and olanzapine first line choices | [6,7,9,10,12,15,17,22,26,33,48,55,128,141,142,158-162] |
SSRIs e.g., paroxetine but risk of mood destabilization | [6,7,9,10,12,15-17,22,25,26,33,48,55,128,157-159,162] | |
Anticonvulsants e.g., valproate, lamotrigine and gabapentin but no strong evidence | [6, 7, 9, 10, 12, 15, 17, 22, 25, 48, 55, 60, 67, 158, 159, 162] | |
Benzodiazepines only for short-term treatment because of risk of abuse and dependence | [6,7,9,10,15-17,22,33,48,162,163] | |
Psychotherapy | ||
Evidence base | Psychotherapy such as CBT may be effective in promoting recovery in those with comorbid anxiety and BD but there are only a few RCTs | [10,22,25,26,162,164-171] |
Principles of treatment | Psychotherapy such as CBT is a first-line add-on treatment option | [6,7,9,12,10,15,17,22,25,26,67,128,157-159,162,164,165] |
- Citation: Spoorthy MS, Chakrabarti S, Grover S. Comorbidity of bipolar and anxiety disorders: An overview of trends in research. World J Psychiatr 2019; 9(1): 7-29
- URL: https://www.wjgnet.com/2220-3206/full/v9/i1/7.htm
- DOI: https://dx.doi.org/10.5498/wjp.v9.i1.7